Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00482989 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

A Phase 1 study of Lupus, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
183
Enrollment target
20
Study locations

NCT00482989: Completed Phase 1 study of Lupus, sponsored by MedImmune.

NCT00482989 is a Phase 1 study of Lupus that has completed, run by MedImmune. The registered enrollment target is 183 participants, below the 271-participant average among 13 other Lupus trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00482989, a Phase 1 study of Lupus, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
183 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the safety and tolerability of multiple IV doses of the MEDIMUNNE antibody in adult patients with SLE.

Conditions Studied

Lupus

Interventions

  • OTHER Placebo
  • BIOLOGICAL MEDI 545

Study Locations (20)

Florida

  • Research Site - Clearwater
  • Research Site - Fort Lauderdale
  • Research Site - Ocala
  • Research Site - Tampa

New York

  • Research Site - Manhasset
  • Research Site - New York
  • Research Site - New York

California

  • Research Site - La Jolla
  • Research Site - Los Angeles

Maryland

  • Research Site - Baltimore
  • Research Site - Bethesda

Texas

  • Research Site - Dallas
  • Research Site - Dallas

Other

  • Research Site - Buenos Aires
  • Research Site - San Miguel de Tucumán

Alabama

  • Research Site - Anniston

Louisiana

  • Research Site - Shreveport

Trial Details

FieldValue
Enrollment Target 183 participants
Start Date 2007-06
Est. Completion 2010-09
Phase Phase 1
MedImmune

210 total trials

What the finished NCT00482989 record still lists

NCT00482989 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 271-participant average among 13 other Lupus trials with a reported enrollment target (32% lower).

The record links to 1 condition, with Lupus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00482989 names 20 study sites across 11 states, led by Florida, New York, California.

Frequently Asked Questions

What is clinical trial NCT00482989 about?

NCT00482989 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus". To evaluate the safety and tolerability of multiple IV doses of the MEDIMUNNE antibody in adult patients with SLE.

What is the current status of trial NCT00482989?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2007-06. Estimated completion is 2010-09.

What conditions does trial NCT00482989 study?

This clinical trial studies the following conditions: Lupus.

What interventions are being tested in trial NCT00482989?

The interventions under investigation include: Placebo (OTHER), MEDI 545 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00482989?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00482989 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00482989's enrollment target sits among peer trials

183 4th of 13 higher than 10 of 13 other Lupus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lupus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03859297 · 183 participants · NA

    Mechanisms of Rumination Change in Adolescent Depression

  • NCT04270591 · 183 participants · Phase 1

    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

  • NCT06764615 · 183 participants · Phase 2

    A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  • NCT06872684 · 183 participants · NA

    Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00482989, the US trial registry maintained by the National Library of Medicine. NCT00482989 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.